# Copper Peptide Hair Growth Research: The GHK-Cu Evidence, Cited > Copper peptide hair growth research, posted line by line: a 6-month RCT showing +71.5 vs +9.6 placebo hair count, AHK-Cu dermal-papilla data, and the angiogenic follicle mechanism. Every figure cited. The controlled human hair-count figure, the analog follicle data, and the angiogenic mechanism — read as a statement, with the combination-versus-monotherapy distinction flagged on every line. ## What the copper peptide hair growth research establishes Copper peptide hair growth research centers on angiogenesis and follicle biology, and the headline figure comes from a controlled human trial. The hair follicle cycles between an active growth phase (anagen) and a resting phase (telogen), and the research thesis is that copper peptides extend anagen and speed re-entry into it. Copper-peptide studies report VEGF induction, microvascular angiogenesis and follicular extracellular-matrix turnover — the same vascular and matrix machinery GHK-Cu drives in skin [6]. The biological logic is consistent with the rest of the GHK-Cu record. The follicle is a high-turnover mini-organ that depends on a rich microvascular supply and continuous matrix remodeling at the dermal papilla, and those are precisely the processes GHK-Cu modulates elsewhere: VEGF and FGF-2 upregulation for angiogenesis, and balanced MMP/TIMP activity for matrix turnover [6]. A copper peptide that lengthens anagen would, on this model, do so by keeping the papilla vascularized and the surrounding matrix in a growth-permissive state rather than by acting on the androgen axis. One distinction governs how every figure below should be read: the strongest controlled human signal comes from a combination formulation, not pure GHK-Cu. This page posts the combination data as a formulation result and the pure-peptide and analog data separately, and never lets the green line stand in for the amber one. The cell-level work uses a close analog, AHK-Cu, rather than GHK-Cu itself — another line where the label matters [12]. This is GHK-Cu-adjacent territory, and the GHK-Cu Store digest treats it the way a statement treats a footnoted entry: the number is real, the caveat is printed next to it. ## The controlled human hair-count figure ### Does copper peptide regrow hair? The strongest controlled human signal is the 6-month ALAVAX trial: hair-count gains of 52.6 (at 100 mg/mL) and 71.5 (at 50 mg/mL) versus 9.6 for placebo (p<0.05), with no adverse events in any group [4]. This was a 5-aminolevulinic-acid + GHK combination, not pure GHK-Cu, so it reads as evidence for the formulation rather than for the bare peptide [4]. The placebo delta of 9.6 frames the effect size: the active arms moved five to seven times further. ### Do copper peptides stimulate hair growth? A 5-ALA + GHK copper-peptide complex significantly increased hair count over placebo in that 45-man trial, and copper-tripeptide analogs stimulate dermal-papilla proliferation and reduce follicle-cell apoptosis in research models [4][12]. The human efficacy evidence is the combination trial; the cellular evidence is the analog work. ### Does copper help hair growth? In the 6-month trial of 45 men, the 5-ALA + GHK copper-peptide complex raised hair count significantly versus placebo [4]; an AHK-Cu copper-tripeptide analog stimulated dermal-papilla proliferation and reduced follicle-cell apoptosis in vitro [12]. Copper enters the picture as a cofactor for the angiogenic and matrix machinery, not as a standalone growth agent. ### Does copper peptide work for hair growth? Research reports copper peptides increase VEGF, stimulate follicular angiogenesis and collagen/glycosaminoglycan turnover, and reduce follicle-cell apoptosis [6][12]; the main human efficacy data come from the combination 5-ALA + GHK formulation [4]. The mechanism is plausible and replicated at the cell level; the controlled human proof is formulation-specific. ## The analog follicle data and the mechanism The cellular evidence for copper-tripeptide hair effects comes mostly from a close analog. AHK-Cu — the alanyl analog of GHK-Cu — at 10⁻¹² to 10⁻⁹ M stimulated elongation of human hair follicles ex vivo and proliferation of dermal papilla cells in vitro, and at 10⁻⁹ M reduced apoptosis, raising the Bcl-2/Bax ratio and lowering cleaved caspase-3 and PARP [12]. AHK-Cu is cited here as analog context, not as GHK-Cu efficacy [12]. The read is anti-apoptotic and pro-proliferative at the follicle, consistent with prolonged anagen. ### Is copper a DHT blocker? Copper-peptide hair effects in research are attributed to angiogenic and anti-apoptotic follicle support, not DHT blockade. The mechanism is VEGF-driven angiogenesis and dermal-papilla anti-apoptosis [6][12], not androgen-pathway inhibition; copper peptides are not studied as 5-alpha-reductase inhibitors, and the evidence does not place them in the DHT-blocking category. ### How long does GHK-Cu take to regrow hair? The pivotal copper-peptide hair trial measured hair-count gains over a 6-month treatment period [4]. Timing for pure GHK-Cu is not established; the controlled evidence is the 6-month combination trial, and any shorter timeline is community guidance rather than a measured result. ### Why the combination distinction matters The ALAVAX figure is the best controlled hair number in the GHK record, and it is for a combination [4]. Pure GHK-Cu monotherapy has no standalone controlled human hair-efficacy trial. A reader scanning this statement should treat the +71.5 line as a formulation result with a green status and the pure-peptide hair claim as an amber, evidence-pending line. --- The GHK-Cu research record kept like an account statement — every collagen figure, hair-count delta and stability constant posted to its source, the gaps flagged in plain sight, and nothing here stocked, priced, or sold.